Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance

LeRoith, 2003, The insulin-like growth factor system and cancer, Cancer Lett, 195, 127, 10.1016/S0304-3835(03)00159-9 Vincent, 2002, Control of cell survival by IGF signaling pathways, Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society, 12, 193, 10.1016/S1096-6374(02)00017-5 Zha, 2010, Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy, Clin Cancer Res: an official journal of the American Association for Cancer Research, 16, 2512, 10.1158/1078-0432.CCR-09-2232 Siddle, 2011, Signalling by insulin and IGF receptors: supporting acts and new players, J Mol Endocrinol, 47, R1, 10.1530/JME-11-0022 Kennedy, 1997, The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal, Genes Dev, 11, 701, 10.1101/gad.11.6.701 Taniguchi, 2006, Critical nodes in signalling pathways: insights into insulin action, Nat Rev Mol Cell Biol, 7, 85, 10.1038/nrm1837 Pouyssegur, 2002, Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling, Biochem Pharmacol, 64, 755, 10.1016/S0006-2952(02)01135-8 Hwa, 1999, The insulin-like growth factor-binding protein (igfbp) superfamily, Endocr Rev, 20, 761 Sachdev, 2007, Disrupting insulin-like growth factor signaling as a potential cancer therapy, Mol Cancer Ther, 6, 1, 10.1158/1535-7163.MCT-06-0080 Pollak, 2004, Insulin-like growth factors and neoplasia, Nat Rev Cancer, 4, 505, 10.1038/nrc1387 Hankinson, 1998, Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, Lancet, 351, 1393, 10.1016/S0140-6736(97)10384-1 Ma, 1999, Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3, J Natl Cancer Inst, 91, 620, 10.1093/jnci/91.7.620 Roberts, 2004, IGF-1 and prostate cancer, Novartis Found Symp, 262, 193, 10.1002/0470869976.ch12 Dziadziuszko, 2008, The insulin-like growth factor pathway in lung cancer, J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer, 3, 815, 10.1097/JTO.0b013e31818180f5 Livingstone, 2013, IGF2 and cancer, Endocr Relat Cancer., 20, R321, 10.1530/ERC-13-0231 Su, 2011, Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma, Oncogene, 30, 3907, 10.1038/onc.2011.97 Luther, 2013, IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma, Cancer Lett, 336, 222, 10.1016/j.canlet.2013.05.002 Chen, 2013, IGF-1R as an anti-cancer target–trials and tribulations, Chin J Cancer, 32, 242, 10.5732/cjc.012.10263 Eccleston, 2006, Signalling in cancer, Nature, 441, 423, 10.1038/441423a Casa, 2008, The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance, Front Biosci: a journal and virtual library, 13, 3273, 10.2741/2925 Florea, 2013, Breast cancer and possible mechanisms of therapy resistance, J Local Glob Health Sci, 2, 1, 10.5339/jlghs.2013.1 Massarweh, 2008, Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function, Cancer Res, 68, 826, 10.1158/0008-5472.CAN-07-2707 Zhang, 2011, Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes, Breast Cancer Res: BCR, 13, R52, 10.1186/bcr2883 Surmacz, 2000, Function of the IGF-I receptor in breast cancer, J Mammary Gland Biol Neoplasia, 5, 95, 10.1023/A:1009523501499 Fox, 2013, Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation, Breast Cancer Res: BCR, 15, R55, 10.1186/bcr3449 Winder, 2014, Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen, Pharmacogenomics J, 14, 28, 10.1038/tpj.2013.8 Li, 2012, IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78, Cancer Lett, 325, 200, 10.1016/j.canlet.2012.07.004 Lu, 2001, Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin), J Natl Cancer Inst, 93, 1852, 10.1093/jnci/93.24.1852 Ye, 2014, Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R, BMC cancer, 14, 134, 10.1186/1471-2407-14-134 Gallardo, 2012, Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas, B J Cancer, 106, 1367, 10.1038/bjc.2012.85 Nahta, 2012, Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance, Chemother Res Pract, 2012, 648965 Karamouzis, 2012, Targeting insulin-like growth factor in breast cancer therapeutics, Crit Rev Oncol Hematol, 84, 8, 10.1016/j.critrevonc.2012.02.010 Liu, 2014, Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer, Oncotarget, 5, 9049, 10.18632/oncotarget.2022 Fagan, 2012, Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment, Cancer Res, 72, 3372, 10.1158/0008-5472.CAN-12-0684 Engelberth, 2014, Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics, Crit Rev Oncog, 19, 281, 10.1615/CritRevOncog.2014011455 Walters Haygood, 2014, Ovarian cancer stem cells: can targeted therapy lead to improved progression-free survival?, World J Stem Cells, 6, 441, 10.4252/wjsc.v6.i4.441 Singh, 2014, IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells, Cancer Lett, 354, 254, 10.1016/j.canlet.2014.08.023 Koti, 2013, Identification of the IGF1/PI3K/NF kappaB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer, BMC Cancer, 13, 549, 10.1186/1471-2407-13-549 Beltran, 2014, Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy, Clin Cancer Res: an official journal of the American Association for Cancer Research, 20, 2947, 10.1158/1078-0432.CCR-13-3448 Brouwer-Visser, 2014, Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer, PloS One, 9, e100165, 10.1371/journal.pone.0100165 SEER Stat Fact Sheets: Prostate Cancer. http://seer.cancer.gov/statfacts/html/prost.html. Wu, 2006, Interaction of IGF signaling and the androgen receptor in prostate cancer progression, J Cell Biochem, 99, 392, 10.1002/jcb.20929 Scher, 2005, Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis, J Clin Oncol: official journal of the American Society of Clinical Oncology, 23, 8253, 10.1200/JCO.2005.03.4777 Taplin, 2004, Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence, J Cell Biochem, 91, 483, 10.1002/jcb.10653 Sharma, 2014, Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival, Prostate, 74, 225, 10.1002/pros.22744 Gray, 2011, Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model, J Endocrinol, 211, 297, 10.1530/JOE-11-0240 Jones, 1993, Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence, Proc Natl Acad Sci U S A, 90, 10553, 10.1073/pnas.90.22.10553 Biernacka, 2013, Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2, Endocr Relat Cancer, 20, 741, 10.1530/ERC-13-0077 Seki, 2013, Restoration of IGFBP-rP1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer, Hiroshima J Med Sci, 62, 13 SEER Stat Fact Sheets: Lung and Bronchus Cancer. Zhang, 2014, The new concepts on overcoming drug resistance in lung cancer, Drug Des Devel Ther, 8, 735 Peled, 2013, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer, Cell Oncol (Dordr), 36, 277, 10.1007/s13402-013-0133-9 Fidler, 2012, Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer, Anticancer Res, 32, 1705 Murakami, 2014, Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor, PloS One, 9, e86459, 10.1371/journal.pone.0086459 Suda, 2014, The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor, Int J Cancer. Journal international du cancer, 135, 1002, 10.1002/ijc.28737 Vazquez-Martin, 2013, IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations, Sci Rep, 3, 2560, 10.1038/srep02560 Riely, 2006, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib, Clin Cancer Res: an official journal of the American Association for Cancer Research, 12, 839, 10.1158/1078-0432.CCR-05-1846 Jackman, 2006, Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib, Clin Cancer Res: an official journal of the American Association for Cancer Research, 12, 3908, 10.1158/1078-0432.CCR-06-0462 Qi, 2011, Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line, Exp Ther Med, 2, 1091, 10.3892/etm.2011.324 Jeannot, 2014, The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism, Int J Cancer. Journal international du cancer, 134, 2560, 10.1002/ijc.28594 Kawai, 2011, The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton, J Biol Chem, 286, 14670, 10.1074/jbc.M110.193334 Hantschel, 2008, Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib, Leuk Lymphoma, 49, 615, 10.1080/10428190801896103 Lu, 2013, IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells, Mol Cancer Ther, 12, 2864, 10.1158/1535-7163.MCT-13-0233 Guix, 2008, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins, J Clin Invest, 118, 2609 Choi, 2013, Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors, PloS One, 8, e81393, 10.1371/journal.pone.0081393 Zimmermann, 2000, Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver, Am J Physiol Gastrointest Liver Physiol, 278, G447, 10.1152/ajpgi.2000.278.3.G447 Cortes-Sempere, 2013, IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer, Oncogene, 32, 1274, 10.1038/onc.2012.146 Sun, 2012, Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells, Int J Radiat Oncol Biol Phys, 82, e563, 10.1016/j.ijrobp.2011.06.1999 Suzuki, 2010, IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype, Carcinogenesis, 31, 342, 10.1093/carcin/bgp179 Okamura, 2012, Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer, Cancer Biol Ther, 13, 148, 10.4161/cbt.13.3.18695 Goodenberger, 2012, Genetics of adult glioma, Cancer Genet, 205, 613, 10.1016/j.cancergen.2012.10.009 Mirimanoff, 2014, High-grade gliomas: reality and hopes, Chin J Cancer, 33, 1, 10.5732/cjc.013.10215 Osuka, 2013, IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells, Stem cells (Dayton, Ohio), 31, 627, 10.1002/stem.1328 Hsieh, 2011, Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells, J Cell Physiol, 226, 1118, 10.1002/jcp.22433 Li, 2011, Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway, PloS One, 6, e27053, 10.1371/journal.pone.0027053 Chen, 2011, Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression, J Neurooncol, 103, 87, 10.1007/s11060-010-0374-7 Fuller, 1999, Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling, Cancer Res, 59, 4228 Han, 2014, Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway, B J Cancer, 111, 1400, 10.1038/bjc.2014.435 Takahashi, 2013, Gastric cancer: current status of diagnosis and treatment, Cancers, 5, 48, 10.3390/cancers5010048 Bochatay, 2014, Pancreatic cancer in 2014: screening and epidemiology, Revue medicale suisse, 10, 1582 Jemal, 2011, Global cancer statistics, CA: Cancer J Clin, 61, 69 Chen, 2007, The evolution of gene regulation by transcription factors and microRNAs, Nat Rev Genet, 8, 93, 10.1038/nrg1990 Cui, 2012, miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies, Mol Biol Cell, 23, 151, 10.1091/mbc.E11-05-0456 Wang, 2014, MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2, Chin Med J, 127, 2357 Yang, 2014, miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2, Anticancer Agents Med Chem, 14, 884, 10.2174/1871520614666140528161318 SEER Stat Fact Sheets: Colon and Rectum Cancer. http://seer.cancer.gov/statfacts/html/colorect.html. Cohen, 2012, Obesity, type 2 diabetes, and cancer: the insulin and IGF connection, Endocr Relat Cancer, 19, F27, 10.1530/ERC-11-0374 Volkova, 2014, Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells, Oncol Lett, 7, 311, 10.3892/ol.2013.1710 Lyman, 2013, Chemotherapy dosing in overweight and obese patients with cancer, Nat Rev Clin Oncol, 10, 451, 10.1038/nrclinonc.2013.108 Haimeur, 2004, The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation, Curr Drug Metab, 5, 21, 10.2174/1389200043489199 Shen, 2012, Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression, J Cell Biochem, 113, 2086, 10.1002/jcb.24080 Hsu, 2014, Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation, Tumour Biol: the journal of the International Society for Oncodevelopmental Biology and Medicine, 35, 303, 10.1007/s13277-013-1041-3 Shan, 2012, Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma, Hepatology (Baltimore, Md.), 56, 1004, 10.1002/hep.25745 Bu, 2014, Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1, PloS One, 9, e89686, 10.1371/journal.pone.0089686 Tian, 2013, Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer, Dig Dis Sci, 58, 2705, 10.1007/s10620-013-2673-2 Morris, 2010, KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma, Nat Rev Cancer, 10, 683, 10.1038/nrc2899 Wei, 2012, K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas, Cancer Lett, 322, 58, 10.1016/j.canlet.2012.02.005 Dropkin, 1999, Body image and quality of life after head and neck cancer surgery, Cancer Pract, 7, 309, 10.1046/j.1523-5394.1999.76006.x So WKW, Chan RJ, Chan DNS, et al. Quality-of-life among head and neck cancer survivors at one year after treatment – a systematic review. Eur J Cancer.48(15):2391–2408. Bier, 1993, Chemotherapeutic drug resistance in the management of head and neck cancer, Eur Arch Otorhinolaryngol: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 250, 200 Szafarowski, 2014, Cancer stem cells in head and neck squamous cell carcinoma, Otolaryngologia polska. The Polish Otolaryngology, 68, 105, 10.1016/j.otpol.2013.10.010 Jameson, 2011, Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells, Mol Cancer Ther, 10, 2124, 10.1158/1535-7163.MCT-11-0294 Knowlden, 2008, Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance, Breast Cancer Res Treat, 111, 79, 10.1007/s10549-007-9763-9 Chung, 2011, Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma, Head Neck, 33, 1804, 10.1002/hed.21478 Limesand, 2013, Impact of targeting insulin-like growth factor signaling in head and neck cancers, Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society, 23, 135, 10.1016/j.ghir.2013.06.001 Kim, 2009, The role of IGF-1R in pediatric malignancies, Oncologist, 14, 83, 10.1634/theoncologist.2008-0189 Wang, 2010, Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo, Mol Cell Biochem, 341, 225, 10.1007/s11010-010-0453-2 Wang, 2009, Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells, Mol Cell Biochem, 327, 257, 10.1007/s11010-009-0064-y Luk, 2011, IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines, Cancer Invest, 29, 521, 10.3109/07357907.2011.606252 Duan, 2009, Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines, Mol Cancer Ther, 8, 2122, 10.1158/1535-7163.MCT-09-0115 Tripathi, 2009, IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo, FASEB J: official publication of the Federation of American Societies for Experimental Biology, 23, 2616, 10.1096/fj.08-114124 de Souza, 2014, Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas, Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society, 24, 130, 10.1016/j.ghir.2014.04.002 Kang, 2013, Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma, Oncogene, 1 Faye, 2014, IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1, Oncogene, 1 Hirose, 2003, Multidrug resistance in hematological malignancy. The journal of medical investigation, JMI, 50, 126 Lichtman, 2008, Battling the hematological malignancies: the 200 years' War, Oncologist, 13, 126, 10.1634/theoncologist.2007-0228 Barrett, 2012, Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies, Paediatr Drugs, 14, 299 Bartalucci, 2013, Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms, J Cell Mol Med, 17, 1385, 10.1111/jcmm.12162 Bauer, 2014, Targeting PI3 kinase in cancer, Pharmacol Ther, 1 Tasian, 2014, Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies, Front Oncol, 4, 108, 10.3389/fonc.2014.00108 Kuhn, 2012, Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma, Blood, 120, 3260, 10.1182/blood-2011-10-386789 Tagoug, 2013, Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors, Clin Cancer Res: an official journal of the American Association for Cancer Research, 19, 3556, 10.1158/1078-0432.CCR-12-3134 Verhagen, 2014, IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival, Cell Death Dis, 5, e1300, 10.1038/cddis.2014.268 Kuhnl, 2011, High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia, Leuk Res, 35, 1585, 10.1016/j.leukres.2011.08.006 Laranjeira, 2012, IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase, Leukemia, 26, 1001, 10.1038/leu.2011.289 King, 2014, Can we unlock the potential of IGF-1R inhibition in cancer therapy?, Cancer Treat Rev, 40, 1096, 10.1016/j.ctrv.2014.07.004